Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

It’s July 20, 1969. Neil Armstrong and Buzz Aldrin are about to land on the moon. They will be the first humans to set foot ...

FORTUNATELY, NOBODY WAS INJURED. CONTROLLING THE PYTHON POPULATION HERE IN FLORIDA, GOVERNOR DESANTIS SPOKE IN STUART TODAY ABOUT SOME NEW ACTIONS THE STATE PLANS TO TAKE TO CONTROL THE GROWTH OF ...

If you are a community college student building Python skills alongside microcontrollers and robotics projects, the PCEP-30-02 certification is your fastest, most credible way to validate those skills ...

BURMESE PYTHONS ARE ONE OF THE STATE’S MOST FEARSOME INVASIVE SPECIES, AND WHILE THEY MAINTAINED A PRESENCE IN THE EVERGLADES FOR MORE THAN 25 YEARS, A NEW STUDY REVEALS THEY’RE TRAVELING NORTH. JJ ...

Recursion is more than a coding trick—it’s a powerful way to simplify complex problems in Python. From elegant tree traversals to backtracking algorithms, mastering recursion opens the door to cleaner ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI alignment and self-improvement.

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...